Protego Bio
United States · $181.0M raised
- Employees
- 1–10
- Business Model
- B2B
- Website
- protegobio.com
- Total Funding
- $181.0M
- Last Round
- $130.0M Series BDec 2025
- Rounds
- 2
About
Protego Bio is a clinical-stage biopharmaceutical company focused on transforming treatment for protein misfolding diseases. The company develops first-in-class small molecule pharmacological chaperones, with a lead program targeting AL amyloidosis.
Summary
Protego Bio is a Biotech company based in United States. It has raised $181.0M in total across 2 rounds, most recently a $130.0M Series B round in Dec 2025. Investors include Lightspeed VP, MPM BioImpact and Novartis Venture Fund.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Dec 2025
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.